Stephen B. Edge, MD of Roswell Park Cancer Institute discusses the importance of personalized medicine, specifically genomic profiling in breast cancer. He states that with more use in genomic profiling, chemotherapy has decreased in need. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
Genomic Profiling is Incorporated in the New AJCC Staging System
